Axitinib: 8 agencies, 2012–2017
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
No agency in this archive has refused axitinib: all 8 decisive outcomes across 7 agencies were positive or positive with restrictions.
The record spans 4.8 years, opening at AWMSG (Wales) on 15 Nov 2012 and running to 21 Sep 2017.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
Nothing has been added since 2017; on this evidence the file is dormant.
Against its own class, axitinib is an outlier: 100% of its decisive outcomes were positive, where molecules sharing ATC class L01E average 75%.
4 distinct indication wordings are recorded for axitinib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
1 of these 9 records carries a year of decision but no day, so any interval quoted here is approximate to within a year.
AWMSG (Wales) was first to assess axitinib, on 15 Nov 2012; G-BA (Germany) did not open a file until 21 Sep 2017 — a wide spread of 4.8 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
HAS (France) is the only agency to have returned to axitinib, recording 2 separate entries.
8 of the 18 agencies in this archive hold a record for axitinib.
The full ledger for axitinib reads 7 recommended, 1 restricted and 1 deferred to NICE.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 21 Sep 2017 | Inlyta — benefit assessment §35a | added benefit: minor (hint) | source |
| PHARMAC (New Zealand) | 25 Aug 2017 | Renal cell carcinoma, metastatic, clear cell, 2nd line | PTAC advice: Low · decision reached | source |
| NICE (England) | 25 Feb 2015 | NICE TA333 | recommended | source |
| PBAC (Australia) | 2014 | Renal cell carcinoma | The PBAC recommended listing axitinib as an Authority Required benefit for the treatment o… | source |
| HAS (France) | 8 Jan 2014 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
4 further decisions for axitinib, across 4 agencies, are not shown here. They link to 4 further source documents.
Related molecules
- cabozantinib — divergent outcome (recommended vs not recommended) on a shared indication
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 9 decisions for axitinib from 8 agencies, 2012 to 2017. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.